MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40256-022-00563-4

Медицинская библиотека · American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023

Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States.

Bhambri Rahul, Colavecchia A Carmine, Bruno Marianna, Chen Yong, Alvir Jose, Roy Anuja, Kemner Jason, Crowley Aaron, Benjumea Darrin, Gilstrap Lauren

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Tafamidis was approved for the treatment of hereditary and wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) in May 2019, based on findings from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).

METHODS

This retrospective cohort study evaluated the factors associated with tafamidis prescription after diagnosis of ATTRwt-CM in the real world. Between May 2019 and December 2020, 430 patients with 6 months' database activity were indexed from the de-identified US Optum electronic healthcare records at first diagnosis of ATTRwt-CM or prescription of tafamidis, then followed until last activity or death. Of these, 209 patients were prescribed tafamidis during follow-up, 167 (80%) within 1 month, 98% by 6 months, and 100% by 9 months. Median time from index to tafamidis prescription, calculated using the Kaplan-Meier method, was 5.8 months (95% confidence interval [CI] 2.4-not evaluable).

RESULTS

Factors associated with tafamidis prescription in a multivariable Cox proportional hazards regression (hazard ratio [95% CI]) included age ≥ 65 years (2.1 [1.07-4.05]), male sex (1.6 [1.07-2.28]), having heart failure/cardiomyopathy (2.4 [1.54-3.82]), and having had technetium-99m pyrophosphate myocardial scintigraphy (1.7 [1.28-2.28]).

CONCLUSIONS

The clinical characteristics of patients with ATTRwt-CM who were prescribed tafamidis in the real world were broadly comparable with those who took part in ATTR-ACT. Further studies are needed to evaluate hereditary and ATTRwt-CM patient populations in the real world and assess the long-term outcomes associated with disease management pathways.

CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier: NCT01994889.

Для цитирования: Bhambri Rahul, Colavecchia A Carmine, Bruno Marianna, Chen Yong, Alvir Jose, Roy Anuja, Kemner Jason, Crowley Aaron, Benjumea Darrin, Gilstrap Lauren. Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States.. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2023. DOI: 10.1007/s40256-022-00563-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.